KOPRAN LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies

2026-08-21 NSE BSE Web 5%ESM-I

Price

196.09

-1.82%
O:199.72
H:201
L:195.11
C:196.09

52W Range

107219
+83%/-10%

Market Cap

₹946.87 Cr

Traded: ₹1.50 Cr (0.16%) 0.0x

Free Float: ₹477.60 Cr (0.31% of FF traded)

Volume · 60D trend

75.83 K 0.0x

Delivery: % 0.0x

View Delivery Data

Returns

1W:+0% 1M:+3% 3M:+1% 6M:+23% 12M:+50%

Valuation

P/E37.9
P/B1.8
P/S1.4
EV/EBIT16.5

Business Strength

ROE7.6%
ROCE9.8%
OPM9.1%
NPM3.8%

Growth (3Y CAGR)

EPS-33.3%
Sales+7.0%
Profit-2.0%
3Y Return+0.0%

Balance Sheet

Debt/Equity0.3
Debt153 Cr
Pledge0.0%
CWIP/Fixed Asset7.2%

Cash Position

CFO/NP257.7%
FCF-0.35 Cr
FCF 3Y Avg-30.7 Cr
Cash/MCap2.0%

Others

Div Yield1.6%
Div Payout56.0%
Cash Conv. Cycle146 days
Tradeable Free Float50.4%

MTF Exposure Trend

60 sessions · funded amount, % of FF, daily delta

Current
₹ 15.34 L
0.03% FF
60d high
₹ 8.40 Cr
60d low
₹ 15.34 L
60d mean
₹ 70.07 L
vs mean
▼ 78.11%

Growth Trends

Metric10Y5Y3Y1YTTMTrend
Sales
+9.0%
+7.0%
+7.0%
--
+12.0%
Stable
ROE
+11.0%
+9.0%
+8.0%
--
--
Decelerating
Return
+14.0%
-4.0%
+0.0%
+14.0%
--
Accelerating
Profit
+8.0%
-16.0%
-2.0%
--
-28.0%
Stable

Quarterly Results

Jun 2026

7 Aug
Rev
154 Cr
+14% YoY-34% QoQ
OPM10.3%
NPM4.3%
PAT
--7 Cr
EPS
-10% YoY1.4

Mar 2026

19 May
Rev
234 Cr
+36% YoY+20% QoQ
OPM14.1%
NPM8.1%
PAT
+95% YoY19 Cr
EPS
+95% YoY3.9

Dec 2025

22 Jan
Rev
194 Cr
+17% YoY+65% QoQ
OPM9.1%
NPM4.8%
PAT
-10% YoY9 Cr
EPS
-10% YoY1.9

Sep 2025

PDF
Rev
118 Cr
-22% YoY-13% QoQ
OPM-4.5%
NPM-8.4%
PAT
-234% YoY-10 Cr
EPS
-235% YoY-2.1

Jun 2025

PDF
Rev
135 Cr
-3% YoY-22% QoQ
OPM10.4%
NPM5.5%
PAT
-33% YoY7 Cr
EPS
-33% YoY1.5

Mar 2025

PDF
Rev
172 Cr
-7% YoY+4% QoQ
OPM9.9%
NPM5.6%
PAT
-48% YoY10 Cr
EPS
-48% YoY2.0

Dec 2024

PDF
Rev
166 Cr
+5% YoY+10% QoQ
OPM11.9%
NPM6.3%
PAT
-34% YoY10 Cr
EPS
-34% YoY2.2

Sep 2024

PDF
Rev
152 Cr
-1% YoY+9% QoQ
OPM9.7%
NPM4.9%
PAT
-46% YoY7 Cr
EPS
-47% YoY1.5

Jun 2024

PDF
Rev
139 Cr
+19% YoY-25% QoQ
OPM13.0%
NPM8.0%
PAT
+301% YoY11 Cr
EPS
+304% YoY2.3

Mar 2024

PDF
Rev
186 Cr
+25% YoY+17% QoQ
OPM11.7%
NPM10.0%
PAT
+132% YoY19 Cr
EPS
+131% YoY3.9

Dec 2023

PDF
Rev
159 Cr
+1% YoY+4% QoQ
OPM14.8%
NPM9.9%
PAT
+127% YoY16 Cr
EPS
+128% YoY3.3

Sep 2023

PDF
Rev
153 Cr
--+30% QoQ
OPM15.0%
NPM9.0%
PAT
+196% YoY14 Cr
EPS
--2.9

Jun 2023

PDF
Rev
117 Cr
---21% QoQ
OPM5.4%
NPM2.4%
PAT
-64% YoY3 Cr
EPS
--0.6

Mar 2023

Rev
149 Cr
---6% QoQ
OPM8.0%
NPM5.4%
PAT
-54% YoY8 Cr
EPS
--1.7

Dec 2022

Rev
158 Cr
----
OPM7.8%
NPM4.4%
PAT
-65% YoY7 Cr
EPS
--1.4

Revenue & Margin Trends

Annual

Quarterly

Balance Sheet Health

Leverage

Debt / Equity0.29
Interest Coverage9.6x
Promoter Pledge0.0%
Borrowings153 Cr

Efficiency

Receivable Days141 days
Inventory Days137 days
Payable Days131 days
Cash Conversion cycle146 days

Cash Position

Operating Cash Flow67 Cr
Investing Cash Flow-65 Cr
Financing Cash Flow-21 Cr
Free Cash Flow-0 Cr

Detailed Financials

Jun 2026PDF ↗
Mar 2026PDF ↗
Dec 2025PDF ↗
Sep 2025PDF ↗
Jun 2025PDF ↗
Mar 2025PDF ↗
Dec 2024PDF ↗
Sep 2024PDF ↗
Jun 2024PDF ↗
Mar 2024PDF ↗
Dec 2023PDF ↗
Sep 2023PDF ↗
Jun 2023PDF ↗
Mar 2023
Dec 2022
Sales154234194118135172166152139186159153117149158
Expenses138201177123121155146137121164135130111137146
Operating Profit163318-5141720151822242361212
OPM %10.3%14.1%9.1%-4.5%10.4%9.9%11.9%9.7%13.0%11.7%14.8%15.0%5.4%8.0%7.8%
Other Income2000330131020242
Interest333233222322222
Depreciation654444444433333
Profit Before Tax92511-1210141410152521184119
Tax %23.8%25.6%13.0%-14.6%24.7%29.4%25.0%23.4%24.7%26.0%23.0%24.6%23.0%26.0%24.0%
Net Profit7199-1071010711191614387
Exceptional Items------------------------------
EPS (Rs)1.43.91.9-2.11.52.02.21.52.33.93.32.90.61.71.4
Sales Growth (YoY)13.9%35.8%16.9%-22.2%-3.0%-7.4%4.6%-0.7%19.2%24.9%0.6%--------
Sales Growth (QoQ)-34.2%20.5%64.8%-12.8%-21.6%3.7%9.7%8.7%-25.1%17.1%4.2%30.4%-21.5%-5.7%--
OP Growth (YoY)11.9%92.7%-10.5%-135.8%-22.2%-21.2%-15.8%-35.5%187.8%80.8%91.4%--------
OP Growth (QoQ)-52.0%85.5%436.4%-137.4%-17.3%-13.9%34.8%-18.9%-16.3%-8.0%3.3%261.8%-47.4%-2.6%--
Profit Growth (YoY)--95.0%-10.0%-234.0%-33.0%-48.0%-34.0%-46.0%301.0%132.0%127.0%196.0%-64.0%-54.0%-65.4%
EPS Growth (YoY)-9.7%94.5%-10.2%-234.6%-33.0%-47.9%-34.1%-46.5%303.5%131.1%127.8%--------
EPS Growth (QoQ)-64.5%101.5%194.2%-233.8%-23.4%-6.9%41.2%-33.5%-40.4%17.7%14.7%401.8%-65.9%16.0%--
OP Margin10.3%14.1%9.1%-4.5%10.4%9.9%11.9%9.7%13.0%11.7%14.8%15.0%5.4%8.1%7.8%
Net Margin4.3%8.1%4.8%-8.4%5.5%5.6%6.3%4.9%8.0%10.0%9.9%9.0%2.4%5.4%4.4%
Material Cost %--63.0%67.0%64.0%63.0%67.0%64.0%64.0%62.0%69.0%63.0%62.0%69.0%66.0%70.0%
Employee Cost %--7.0%9.0%14.0%11.0%10.0%9.0%10.0%10.0%7.0%9.0%9.0%11.0%10.0%8.0%
P/S1.351.351.29------------------------
P/E37.8635.7748.16------------------------
P/B1.791.741.59------------------------

Shareholding Pattern

Shareholders:56.9K (+36.9%)
Current MixJun 2026

Exchange Filings

50
AGM/EGM18 Aug 2026

Proceedings of AGM, Voting results and Scrutinzer report

Company Update10 Aug 2026

Result Q1 FY 2026-27

Result07 Aug 2026

Unaudited Standalone and Consolidated Result for the quarter ended June 30, 2026

Company Update07 Aug 2026

For Q1 FY 2026-27

Board Meeting07 Aug 2026

Unaudited Standalone and Consolidated Result for the Quarter Ended June 30, 2026

Others25 Jul 2026

Annual report 2026

Board Meeting22 Jul 2026

Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Results for the Q1 FY 2026-27

Corp. Action16 Jul 2026

Record Date for Payment of Dividend

Company Update09 Jul 2026

for the Quarter 1 FY 2026-27

Company Update26 Jun 2026

Appointment of Mr. Vijay L Thange as Chief Technical Officer (CTO) of the Company.

Insider Trading / SAST24 Jun 2026

Closure of Trading Window for Q1 FY 2026-27

AGM/EGM04 Jun 2026

Outcome of NCLT convened meeting for equity shareholders, secured creditor and unsecured creditor held on 03.06.2026

Company Update22 May 2026

Annual Secretarial Compliance Report for the year ended March 31, 2026

Company Update21 May 2026

Newspaper Advertisement for the Q4 Results FY 2025-26

Company Update20 May 2026

Investor presentation for 2026.

Board Meeting19 May 2026

Standalone and Consolidated Audited Financial result for the Fourth quarter and Year ended on March 31, 2026.

Company Update18 May 2026

Appointment of Director & Issue of shares in Subsidiary company Kopran Research laboratories ltd

AGM/EGM07 May 2026

Notice of shareholders meeting convened by NCLT to be held on June 03,2026

Board Meeting06 May 2026

Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Audited ....

Company Update04 May 2026

Newspaper Advertisement pursuant to NCLT Order dated April 09, 2026 Mumbai Bench, for Notice served to the members, creditors, for the approval of Scheme of Amalgamation.

AGM/EGM30 Apr 2026

Notice convening the Meeting of Equity Shareholders, Secured and Unsecured Creditors of Transferee and Transferor Company pursuant to NCLT order dated April 09, 2026.

Company Update10 Apr 2026

Pronouncement of NCLT order dated April 09, 2026 for Scheme of Amalgamation.

Company Update10 Apr 2026

Clarification on Price Movement

Company Update10 Apr 2026

The Exchange has sought clarification from Kopran Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....

BSE
Company Update09 Apr 2026

Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended March 31, 2026.

Company Update08 Apr 2026

Company reply to BSE surveillance letter on volume movement

Company Update08 Apr 2026

The Exchange has sought clarification from Kopran Ltd on April 8, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.

BSE
Insider Trading / SAST24 Mar 2026

Closure of trading window

Company Update17 Mar 2026

Resignation of Non Executive Non- Independent Director Mr. Adarsh Somani (DIN:00192609)

Company Update28 Feb 2026

Observation letter from NSE

Company Update27 Feb 2026

Observation Letter with no adverse observations from Bombay Stock Exchange of India (BSE Limited) on Scheme of Amalgamation Received.

Company Update20 Feb 2026

Cyber-attack at Khopoli Factory

Company Update23 Jan 2026

Investor Presentation for Q3 FY 2025-26

Company Update23 Jan 2026

Newspaper Advertisement for the Q3 Results FY 2025-26

Board Meeting22 Jan 2026

Unaudited Results for standalone and consolidated for Q3 FY 2025-26

Company Update21 Jan 2026

Disclosure under Regulation 30 SEBI (LODR) 2015 -Inspection /search by GST Authorities

Board Meeting13 Jan 2026

Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/01/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....

Company Update08 Jan 2026

for the Quarter ended December 31, 2025

Company Update01 Jan 2026

CRISIL has Reaffirmed the Credit Rating till March 31, 2026

Insider Trading / SAST26 Dec 2025

The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kumkum Somani & Others

Insider Trading / SAST23 Dec 2025

Results for the third quarter ended December 31, 2025

Company Update02 Dec 2025

Results for the Quarter ended September 30, 2025

Company Update12 Nov 2025

Investor Presentation for Financial Year Q2 2025-26 Result

Company Update12 Nov 2025

Investor Presentation on Q2 FY 2025-26 results

Board Meeting12 Nov 2025

Results for the Quarter ended September 30, 2025

Board Meeting30 Oct 2025

Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve unaudited Standalone and Consolidated ....

Company Update10 Oct 2025

Compliance Certificate for the Quarter ended September 30,2025

Insider Trading / SAST25 Sept 2025

For Quarter ended September 30,2025

Company Update18 Sept 2025

Retirement of Director(s)

Insider Trading / SAST15 Sept 2025

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kumkum Somani & PACs

Annual Reports

15

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

Credit Ratings

6
crisilRating update
24 Dec 2025Report
crisilRating update
26 Sept 2025Report
crisilRating update
30 Jun 2025Report
crisilRating update
01 Apr 2025Report
crisilRating update
03 Sept 2024Report
crisilRating update
05 Sept 2023Report

Concalls

20

Jan 2026

31 Jan 2026

Nov 2025

30 Nov 2025

Nov 2025

30 Nov 2025

Jul 2025

31 Jul 2025

May 2025

31 May 2025

Mar 2025

31 Mar 2025

Feb 2025

28 Feb 2025

Feb 2025

28 Feb 2025

Nov 2024

30 Nov 2024

Aug 2024

31 Aug 2024

Aug 2024

31 Aug 2024

May 2024

31 May 2024

Feb 2024

29 Feb 2024

Feb 2024

29 Feb 2024

Nov 2023

30 Nov 2023

May 2022

31 May 2022

Nov 2021

30 Nov 2021

Jun 2021

30 Jun 2021

Feb 2021

28 Feb 2021

Nov 2020

30 Nov 2020

Held by ETFs

1 ETFs hold kopran · sorted by weight

#ETFWeight %
1

MOHEALTH

MOTILALAMC - MOHEALTH

0.03%

Held by Mutual Funds

1 schemes hold kopran · sorted by weight

#SchemeWeight %
1

Bandhan BSE Healthcare Index Fund

Bandhan Mutual Fund

0.03%